CXCR4-using HIV variants in a cohort of Black men who have sex with men: HIV Prevention Trials Network 061

References

• Verhofstede C, Nijhuis M, Vandekerckhove L. Correlation of coreceptor usage and disease progression. Curr Opin HIV AIDS. 2012;7(5):432–439.10.1097/COH.0b013e328356f6f2
   PubMed Web of Science ®Google Scholar
• Raymond S, Delobel P, Mavigner M, et al. CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. AIDS. 2010;24(15):2305–2312.
   PubMed Web of Science ®Google Scholar
• Chalmet K, Dauwe K, Foquet L, et al. Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: Correlates and evidence for transmission. J Infect Dis. 2012;205(2):174–184.10.1093/infdis/jir714
   PubMed Web of Science ®Google Scholar
• Sierra-Enguita R, Rodriguez C, Aguilera A, et al. X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain. AIDS. 2014;28(11):1603–1609.10.1097/QAD.0000000000000269
   PubMed Web of Science ®Google Scholar
• de Mendoza C, Van Baelen K, Poveda E, et al. Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters. J Acquir Immune Defic Syndr. 2008;48(3):241–244.10.1097/QAI.0b013e3181734f0e
   PubMed Web of Science ®Google Scholar
• Schuitemaker H, van ‘t Wout AB, Lusso P. Clinical significance of HIV-1 coreceptor usage. J Transl Med. 2011;9(Suppl 1):S5.
   PubMed Web of Science ®Google Scholar
• de Mendoza C, Rodriguez C, Garcia F, et al. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. J Antimicrob Chemother. 2007;59(4):698–704.10.1093/jac/dkm012
   PubMed Web of Science ®Google Scholar
• Chen BA, Panther L, Marzinke MA, et al. Phase 1 safety, pharmacokinetics, and pharmacodynamics of dapivirine and maraviroc vaginal rings. J Acquir Immune Defic Syndr. 2015;70(3):242–249.10.1097/QAI.0000000000000702
   PubMed Web of Science ®Google Scholar
• Gulick RM, Wilkin TJ, Chen YQ, et al. HPTN 069/ACTG 5305: Phase II study of maraviroc-based regimens for HIV PrEP in MSM. Conference on Retroviruses and Opportunistic Infections. Boston, MA. February 22–25, 2016.
   Google Scholar
• Koblin BA, Mayer KH, Eshleman SH, et al. Correlates of HIV acquisition in a cohort of Black men who have sex with men in the United States: HIV Prevention Trials Network (HPTN) 061. PLoS One. 2013;8(7):e70413.10.1371/journal.pone.0070413
   PubMed Web of Science ®Google Scholar
• Mayer KH, Wang L, Koblin B, et al. Concomitant socioeconomic, behavioral, and biological factors associated with the disproportionate HIV infection burden among Black men who have sex with men in 6 U.S. cities. PLoS One. 2014;9(1):e87298.10.1371/journal.pone.0087298
   PubMed Web of Science ®Google Scholar
• Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother. 2007;51(2):566–575.10.1128/AAC.00853-06
   PubMed Web of Science ®Google Scholar
• Reeves JD, Coakley E, Petropoulos CJ, Whitcomb JM. An enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: A review of analytical and clinical studies. J Viral Entry. 2009;3(3):94–102.
   Google Scholar
• Huang W, Eshleman SH, Toma J, et al. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: High prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol. 2007;81(15):7885–7893.10.1128/JVI.00218-07
   PubMed Web of Science ®Google Scholar
• Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol. 2007;25(12):1407–1410.10.1038/nbt1371
   PubMed Web of Science ®Google Scholar
• Vandekerckhove LP, Wensing AM, Kaiser R, et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis. 2011;11(5):394–407.10.1016/S1473-3099(10)70319-4
   PubMed Web of Science ®Google Scholar
• Chen I, Cummings V, Fogel JM, et al. Low-level viremia early in HIV infection. J Acquir Immune Defic Syndr. 2014;67(4):405–408.10.1097/QAI.0000000000000298
   PubMed Web of Science ®Google Scholar
• Chen I, Connor MB, Clarke W, et al. Antiretroviral drug use and HIV drug resistance among HIV-infected Black men who have sex with men: HIV Prevention Trials Network 061. J Acquir Immune Defic Syndr. 2015;69(4):446–452.
   PubMed Web of Science ®Google Scholar
• Huang W, Toma J, Stawiski E, et al. Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals. AIDS Res Hum Retroviruses. 2009;25(8):795–802.10.1089/aid.2008.0252
   PubMed Web of Science ®Google Scholar
• Obermeier M, Symons J, Wensing AM. HIV population genotypic tropism testing and its clinical significance. Curr Opin HIV AIDS. 2012;7(5):470–477.10.1097/COH.0b013e328356eaa7
   PubMed Web of Science ®Google Scholar
• Lin NH, Becerril C, Giguel F, et al. Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C. Virology. 2012;433(2):296–307.10.1016/j.virol.2012.08.013
   PubMed Web of Science ®Google Scholar
• Frange P, Galimand J, Goujard C, et al. High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996–2007: The French ANRS CO06 PRIMO cohort study. J Antimicrob Chemother. 2009;64(1):135–141.10.1093/jac/dkp151
   PubMed Web of Science ®Google Scholar
• Audigé A, Taffé P, Rickenbach M, et al. Low postseroconversion CD4 count and rapid decrease of CD4 density identify HIV + fast progressors. AIDS Res Hum Retroviruses. 2010;26(9):997–1005.10.1089/aid.2009.0263
   PubMed Web of Science ®Google Scholar
• Olson AD, Guiguet M, Zangerle R, et al. Evaluation of rapid progressors in HIV infection as an extreme phenotype. J Acquir Immune Defic Syndr. 2014;67(1):15–21.10.1097/QAI.0000000000000240
   PubMed Web of Science ®Google Scholar
• Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med. 2013;368(3):218–230.10.1056/NEJMoa1110187
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Antiretroviral drugs used in the treatment of HIV infection. 2015. http://www.fda.gov/ForPatients/Illness/HIVAIDS/Treatment/ucm118915.htm. Accessed December 8, 2015.
   Google Scholar
• Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine‐lamivudine, for the treatment of antiretroviral‐naive subjects with CCR5‐tropic HIV‐1 infection. J Infect Dis. 2010;201(6):803–813.10.1086/650499
   PubMed Web of Science ®Google Scholar
• Symons J, van Lelyveld SF, Hoepelman AI, et al. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient. J Antimicrob Chemother. 2011;66(4):890–895.10.1093/jac/dkq535
   PubMed Web of Science ®Google Scholar
• Svicher V, Balestra E, Cento V, et al. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. Antiviral Res. 2011;90(1):42–53.10.1016/j.antiviral.2011.02.005
   PubMed Web of Science ®Google Scholar
• Surdo M, Alteri C, Puertas MC, et al. Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029. Clin Microbiol Infect. 2015;21(1):103.e1–103.e6.
   PubMedGoogle Scholar
• Mannheimer SB, Wang L, Wilton L, et al. Infrequent HIV testing and late HIV diagnosis are common among a cohort of black men who have sex with men in 6 US cities. J Acquir Immune Defic Syndr. 2014;67(4):438–445.10.1097/QAI.0000000000000334
   PubMed Web of Science ®Google Scholar